FOLH1 and prostate carcinoma: In a similar study, cisplatin prodrug (as conjugated to PLA backbone) and free irinotecan loaded into PLGA–PEG NPs to target prostate-specific membrane antigen (PSMA) overexpressing prostate cancer cell using S,S-2-(3-[5-amino-1-carboxypentyl]-ureido)-pentanedioic acid ligand.60 Addition of cisplatin–PLA to the solution of PLGA–PEG with irinotecan increased its encapsulation efficiency from 10% up to 44%.